The NewYork-Presbyterian (NYP) and Weill Cornell Medicine (WCM) Bone Marrow Transplant and Cellular Therapy Program is a leading center for hematologic malignancy and cellular therapy medicine in New York. Serving patients from around New York City, across the country and throughout the world, NewYork-Presbyterian Hospital is ranked 7 in the nation, according to U.S. News and World Report’s annual survey of “Best Hospitals.” The WCM/NYP Bone Marrow Transplant and Cellular Therapy Program performs approximately 200 transplants and infusions every year, which includes autologous and allogeneic transplants, as well as CAR-T cells. These include the use of cord blood units and haploidentical + cord blood protocols in order to provide transplantation as a treatment option to more diverse patient populations and those without matching donors.
NYP-Weill Cornell is Magnet certified and FACT accredited for autologous and allogeneic transplant, Immune Effector Cell Therapy, and Product Processing. Weill Cornell Medicine physicians are leaders in their field and committed to advancing outcomes through clinical and translational research. This includes offering observational as well as interventional studies to our patients. We have numerous clinical trials available, including investigator-initiated trials, NCI and NIH sponsored national trials, cooperative group trials, and industry-sponsored trials.